Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Emerging Pharmaceutical Market: China Introduction | 7 | 4 |
| GBI Research Report Guidance | 10 | 1 |
| Emerging Pharmaceutical Market: China Macroeconomic Environment | 11 | 4 |
| Demographic Analysis | 11 | 2 |
| PEST Analysis | 13 | 1 |
| Political Factors | 13 | 1 |
| Economic Factors | 14 | 1 |
| Social Factors | 14 | 1 |
| Technological Factors | 14 | 1 |
| Emerging Pharmaceutical Market: China Industry Performance | 15 | 17 |
| China (Past, Present and Future Scenario) | 15 | 1 |
| Macroeconomic Indicators | 15 | 4 |
| Population Profile | 19 | 1 |
| Environmental Burden of Disease | 19 | 1 |
| Number of Major Infections in China | 19 | 1 |
| Number of Deaths Occurring by Diseases in China | 20 | 1 |
| HIV/AIDS | 21 | 1 |
| Cardiovascular Diseases (CVD) | 22 | 1 |
| Diabetes | 23 | 1 |
| Cancer | 24 | 1 |
| Chronic Obstructive Pulmonary Diseases (COPD) | 25 | 1 |
| Healthcare Spending and Financing | 26 | 1 |
| Imports and Exports | 27 | 2 |
| Branded and Generic Drugs | 29 | 1 |
| Healthcare Infrastructure | 29 | 1 |
| Key Players in the Hospital Section | 30 | 2 |
| Emerging Pharmaceutical Market: China Pharma and Biotech Industry | 32 | 22 |
| Pharmaceutical Market Size and Growth in China | 32 | 1 |
| Biotech Market Size and Growth in China | 33 | 1 |
| Major Regulatory Bodies in China | 34 | 1 |
| SFDA (State Food and Drug Administration) | 34 | 1 |
| CDE (Center for Drug Evaluation) | 34 | 1 |
| NDRC (National Development and Reform Commission) | 35 | 1 |
| NICPBP (National Institute for the Control of Pharmaceutical and Biological Products) | 35 | 1 |
| Key Pharmaceutical Regulations in China | 36 | 1 |
| Ministry of Health | 36 | 1 |
| Provincial Department of Health | 36 | 1 |
| City Department of Health | 36 | 1 |
| Township Department of Health | 36 | 1 |
| Village Health Administration | 36 | 1 |
| The National Development and Reform Commission | 37 | 1 |
| Chinese Center for Disease Control and Prevention (China CDC) | 37 | 1 |
| The Ministry of Finance | 37 | 1 |
| Ministry of Labor and Social Security (MoLSS) | 37 | 1 |
| Pricing and Reimbursement in China | 38 | 1 |
| Pricing of Pharmaceutical Drugs in China | 38 | 1 |
| Reimbursements of Pharmaceutical Drugs in China | 39 | 1 |
| Intellectual Property Rights in China | 39 | 1 |
| Patent Law | 40 | 1 |
| Trademark Law | 40 | 1 |
| Anti-Unfair Competition Law | 41 | 1 |
| Regulations on Customs Protection of Intellectual Property Rights | 42 | 1 |
| Key Marketing and Distribution Channels in China | 42 | 1 |
| Current Distribution Situation in China | 43 | 1 |
| Modern Pharmaceutical Logistics in China | 43 | 1 |
| Foreign-Invested Distributors in China | 43 | 1 |
| Key Distributors Foreign | 44 | 1 |
| AstraZeneca China | 44 | 1 |
| Bayer Schering Pharma China | 44 | 1 |
| Shanghai Roche Pharmaceutical Corp. | 44 | 1 |
| Xian-Janssen (Johnson &Johnson) | 44 | 1 |
| Sanofi-Aventis | 44 | 1 |
| Key Distributors Domestic | 45 | 1 |
| Sinopharm Group Co. Ltd. | 45 | 1 |
| Shanghai Pharmaceutical Co. Ltd. | 45 | 1 |
| Jointown Group Corp | 46 | 1 |
| Harbin Pharmaceutical Group Corp. | 46 | 1 |
| Taiji Group Corp. | 46 | 1 |
| M&A Deals | 47 | 1 |
| Top 10 Deals Summary Between 2009 and 2011 | 47 | 1 |
| Shanghai Pharmaceutical to Acquire CITIC Pharmaceutical, announced January 2011 | 47 | 1 |
| Shanghai Pharmaceutical Completes Acquisition Of 55% Stake in China Health System, in 2011 | 47 | 1 |
| Shanghai Pharmaceutical to Acquire Stake in SIIC Medical Science, Mergen Biotech and In Shanghai Fudan-zhangjiang Bio-Pharmaceutical, announced the same in 2009 | 47 | 1 |
| Sinopharm to Acquire 60% Stake in Shijiazhuang Lerentang, announced in 2011 | 47 | 1 |
| Shenzhen Accord Pharmaceutical to Acquire 52% Stake in Sinopharm Holdings Shenzhen TCM, announced the same on 2010 | 47 | 1 |
| Roche Holding Enters Into Co-Development Agreement with Aileron Therapeutics, in 2011 | 48 | 1 |
| Sanofi-Aventis Extends Its Tender Offer to Acquire Genzyme, announced in 2010 | 48 | 1 |
| Johnson &Johnson Acquires Crucell, in 2011 | 48 | 1 |
| Roche Holding Acquires Marcadia Biotech, 2010 | 48 | 1 |
| AstraZeneca Acquires Novexel, in 2010 | 48 | 1 |
| Licensing Agreements | 49 | 1 |
| Top 10 Licensing Deals Summary Between 2009 and 2011 | 49 | 1 |
| Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca, in 2009 | 49 | 1 |
| AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals, in 2010 | 49 | 1 |
| PTC Therapeutics Enters Into Licensing Agreement with F. Hoffmann-La Roche, in 2009 | 49 | 1 |
| Avila Therapeutics Enters into Licensing Agreement with Sanofi-Aventis, in 2010 | 49 | 1 |
| Algeta Signs Licensing Agreement with Bayer, in 2009 | 50 | 1 |
| Shanghai Institutes For Biological Sciences Enters Into Licensing Agreement with Sanofi-Aventis, in 2010 | 50 | 1 |
| Prometheus Laboratories Signs Licensing Agreement with Bayer Schering Pharma, in 2010 | 50 | 1 |
| Targacept Expands License Agreement with AstraZeneca, in 2009 | 50 | 1 |
| Ascenta Therapeutics Enters Into Licensing Agreement with Sanofi-Aventis, in 2010 | 50 | 1 |
| Digital Biotech Enters Into Licensing Agreement with Roche Holding, in 2010 | 51 | 1 |
| Market Drivers and Restraints | 51 | 1 |
| Market Drivers | 52 | 1 |
| High Growth in Medical Equipment Market | 52 | 1 |
| Growth in Pharmaceutical Industry Sector | 52 | 1 |
| Booming Healthcare Construction Market | 52 | 1 |
| Opportunity in Hospital Information Systems Sector | 52 | 1 |
| Market Restraints | 52 | 1 |
| Regulatory and Bureaucratic issues | 52 | 1 |
| Weak Intellectual Property Protection | 52 | 1 |
| High Cost of Prescription Drugs | 53 | 1 |
| Financial Disparity and Coverage Problems | 53 | 1 |
| Inadequate Infrastructure and Qualified Workforce | 53 | 1 |
| Language Barrier | 53 | 1 |
| Emerging Pharmaceutical Market: China Service Industries Contract Research and Manufacturing Services (CRAMS) | 54 | 26 |
| Introduction | 54 | 1 |
| CMO Market Size and Growth in China | 54 | 1 |
| Key CMO Companies Domestic | 55 | 1 |
| Shanghai Pharmaceutical Group | 55 | 1 |
| Zhejiang Hisun Pharma | 55 | 1 |
| WuXi AppTech | 55 | 1 |
| Shandong Xinhua Pharmaceutical | 56 | 1 |
| Tianjin Pharmaceutical | 56 | 1 |
| Shandong Lukang Pharmaceutical | 56 | 1 |
| Key CMO Companies Foreign | 57 | 1 |
| Lonza | 57 | 1 |
| Boehringer Ingelheim | 58 | 1 |
| DSM | 59 | 1 |
| Evonik | 60 | 1 |
| Dalian Pfizer Pharmaceutical Co. | 61 | 1 |
| CMO Market Drivers and Restraints | 62 | 1 |
| CMO Market Drivers | 62 | 1 |
| Increased Utilization of Biologics for Disease Therapy | 62 | 1 |
| Increase in Number of Government Sanctions and Policies Favoring CMOs | 62 | 1 |
| CMO Market Restrains | 63 | 1 |
| Regulatory Approvals | 63 | 1 |
| Insufficient Communication Platform | 63 | 1 |
| CRO Market Size and Growth in China | 63 | 2 |
| Key CRO Companies Domestic | 65 | 1 |
| Wuxi Pharma Tech. | 65 | 1 |
| Shanghai ChemPartner Co. Ltd. | 66 | 1 |
| Shanghai Genomics, Inc. | 67 | 1 |
| Zensun (Shanghai) Sci &Tech Co., Ltd. | 68 | 1 |
| Shanghai LeadDiscovery Pharma | 69 | 1 |
| Key CRO Companies Foreign | 70 | 1 |
| Quintiles Transnational Corp | 70 | 1 |
| Covance | 71 | 1 |
| Pharmaceutical Product Development Inc. (PPD) | 72 | 1 |
| Charles River Laboratories | 73 | 1 |
| PAREXEL International | 74 | 1 |
| Top 10 Deals Summary Between 2009 to 2011 | 75 | 1 |
| Royal DSM Acquires Martek Biosciences, in 2011 | 75 | 1 |
| Boehringer Ingelheim Acquires Additional 33.6% Stake in SSP, in 2010 | 75 | 1 |
| Pharmaceutical Product Acquires BioDuro, in 2009 | 75 | 1 |
| Royal DSM Acquires Microbia from Ironwood Pharmaceuticals, in 2010 | 75 | 1 |
| Charles River Laboratories Acquires Cerebricon, in 2009 | 75 | 1 |
| Tianjin Chase Sun Pharmaceutical to Acquire Minority Stake in Tcmages Pharmaceutical, 2010 | 75 | 1 |
| QPS and Quintiles Collaborates for Cardiac Safety Service | 76 | 1 |
| Covance and Eli Lilly Entered into a Strategic R&D Collaboration | 76 | 1 |
| Charles River Acquired Systems Pathology Company | 76 | 1 |
| Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities through Alliance with Optasia | 76 | 1 |
| Top 10 Licensing Summary Between 2009 to 2011 | 76 | 1 |
| f-star Biotechnologische Enters Into Licensing Agreement With Boehringer Ingelheim, in 2010 | 76 | 1 |
| Lpath Enters Into Licensing Agreement with Pfizer, in 2010 | 76 | 1 |
| Cleveland BioLabs Enters Into Licensing Agreement with Zhejiang Hisun Pharmaceutical | 76 | 1 |
| Roswell Park Cancer Institute Enters Into Licensing Agreement with Zhejiang Hisun Pharmaceutical, in 2010 | 77 | 1 |
| The Medicines Company Enters Into Licensing Agreement with Pfizer, in 2009 | 77 | 1 |
| Covance Agreed to Provide Genomic Analysis Services to Merck &Co., Inc., in 2009 | 77 | 1 |
| Seattle Genetics Enters Into Licensing Agreement with Pfizer, in 2011 | 77 | 1 |
| Depomed Enters Into Licensing Agreement with Boehringer Ingelheim, in 2011 | 77 | 1 |
| Biocon Enters Into Licensing Agreement with Pfizer, in 2010 | 78 | 1 |
| Covance Enters Into an Agreement with Sanofi-Aventis, in 2010 | 78 | 1 |
| CRO Market Drivers and Restrains | 78 | 1 |
| CRO Market Drivers | 79 | 1 |
| Increasing R&D Expenditure and Decreasing Productivity in the Biopharmaceutical Industry Promoting R&D Outsourcing | 79 | 1 |
| Availability of a Large Pool of Clinical Scientists | 79 | 1 |
| The Chinese Government Has Encouraged Foreign Investment | 79 | 1 |
| CRO Market Restraints | 79 | 1 |
| Intellectual Property Issues Are Not Fully Resolved | 79 | 1 |
| In-depth Training in GCP s for Health Care Professional | 79 | 1 |
| Emerging Pharmaceutical Market: China Service Industries Healthcare IT | 80 | 1 |
| Healthcare IT Market Size and Growth in China | 80 | 1 |
| Emerging Pharmaceutical Market: China Appendix | 81 | 5 |
| Market Definitions | 81 | 1 |
| Abbreviations | 81 | 1 |
| Research Methodology | 82 | 2 |
| Coverage | 82 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Expert Panel Validation | 83 | 1 |
| Contact Us | 84 | 1 |
| Disclaimer | 84 | 1 |
| Sources | 84 | 2 |